| 产品介绍 | | |
| Sheep anti Human C1q antibodyrecognizes human C1q, a sub-component of complement C1. C1q associates with complement components C1r and C1s, which are required for the progression of the proteolytic complement cascade. Deficiency of C1q has been associated with lupus erythematosus and glomerulonephritis (Troedsonet al.2013).Sheep anti human C1q antibody may cross react with C1q in other species. |
| 产品详情 | | |
Target Species | Human |
Product Form | Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid |
Antiserum Preparation | Antisera to human C1q were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG was prepared from whole serum by protein G affinity chromatography. |
Buffer Solution | Phosphate buffered saline |
Preservative Stabilisers | 0.01% Thiomersal |
Approx. Protein Concentrations | IgG concentration 1.0 mg/ml |
Immunogen | Human C1q. |
Regulatory | For research purposes only |
Guarantee | 12 months from date of despatch |
| 存储条件 | | |
| This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. |
| 应用 | | |
Application Name | Verified | Min Dilution | Max Dilution |
ELISA | √ | 1/100 | 1/400 |
| This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit theantibody protocolspage.Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls. |
| 二抗相关产品 |
Description | Product Code | Applications | Pack Size |
| AbGUARD® HRP Stabilizer Plus | BUF052A | C;E;P;WB | 100 ml |
| AbGUARD® HRP Stabilizer Plus | BUF052B | C;E;P;WB | 500 ml |
| AbGUARD® HRP Stabilizer Plus | BUF052C | C;E;P;WB | 1000 ml |
| TMB Signal+ | BUF054A | ELISA | 100 ml |
| TMB Core | BUF056A | ELISA | 100 ml |
| 数据 |
Published customer image:Sheep anti Human C1q antibody (2221-5004P) used to evaluate C1q levels in plasma samples by ELISA.Image caption:Levels of factors of the CP and LP; plotted values are nonlog for ease of comprehension.(A) Plasma levels of C1q, (B) MBL oligomer, (C) C-reactive protein, and (D) immunocomplex-CIC-C1q in dengue-infected individuals at different stages of infection (acute and convalescent) and in healthy subjects. All complement proteins were measured by ELISA. Values shown are means and standard deviations. The p-values of two-tailed t-tests on the log-transformed data are indicated above each analysis. |
| 文献 |
| 1. Nascimento, E.J.et al. (2009) Alternative complement pathway deregulation is correlated with dengue severity.PLoS One. 4:e67822. Lewis, M.J.et al.(2007) The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.Mol Immunol. 45: 818-27.3. Jacobs, B.C.et al.(2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.Brain. 126: 2220-34.4. Arduin, E.et al.(2015) Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.Mol Immunol. 63 (2): 456-63.5. Kao, D.et al.(2015) A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors.Cell Rep. 13 (11): 2376-85.6. Gearing, D.P.et al.(2016)In VitroandIn VivoCharacterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.J Vet Intern Med. 30 (4): 1129-37. |
QQ:1749072012